Literature DB >> 19783380

Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer.

Iris Gluck1, Felix Y Feng, Teresa Lyden, Marc Haxer, Francis Worden, Douglas B Chepeha, Avraham Eisbruch.   

Abstract

PURPOSE: Reporting long-term toxicities in trials of chemoirradiation (CRT) of head-and-neck cancer (HNC) has mostly been limited to observer-rated maximal Grades >or=3. We evaluated this reporting approach for dysphagia by assessing patient-reported dysphagia (PRD) and objective swallowing dysfunction through videofluoroscopy (VF) in patients with various grades of maximal observer-reported dysphagia (ORD). METHODS AND MATERIALS: A total of 62 HNC patients completed quality-of-life questionnaires periodically through 12 months post-CRT. Five PRD items were selected: three dysphagia-specific questions, an Eating-Domain, and "Overall Bother." They underwent VF at 3 and 12 months, and ORD (Common Terminology Criteria for Adverse Events) scoring every 2 months. We classified patients into four groups (0-3) according to maximal ORD scores documented 3-12 months post-CRT, and assessed PRD and VF summary scores in each group.
RESULTS: Differences in ORD scores among the groups were considerable throughout the observation period. In contrast, PRD scores were similar between Groups 2 and 3, and variable in Group 1. VF scores were worse in Group 3 compared with 2 at 3 months but similar at 12 months. In Group 1, PRD and VF scores from 3 through 12 months were close to Groups 2 and 3 if ORD score 1 persisted, but were similar to Group 0 in patients whose ORD scores improved by 12 months.
CONCLUSIONS: Patients with lower maximal ORD grades, especially if persistent, had similar rates of PRD and objective dysphagia as patients with highest grades. Lower ORD grades should therefore be reported. These findings may have implications for reporting additional toxicities besides dysphagia. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19783380      PMCID: PMC2878868          DOI: 10.1016/j.ijrobp.2009.05.049

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  51 in total

1.  Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

Authors:  G Calais; M Alfonsi; E Bardet; C Sire; T Germain; P Bergerot; B Rhein; J Tortochaux; P Oudinot; P Bertrand
Journal:  J Natl Cancer Inst       Date:  1999-12-15       Impact factor: 13.506

2.  Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer.

Authors:  J B Sunwoo; L L Herscher; G S Kroog; G R Thomas; F G Ondrey; D C Duffey; B I Solomon; C Boss; P S Albert; L McCullugh; S Rudy; C Muir; S Zhai; W D Figg; J A Cook; J B Mitchell; C Van Waes
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

3.  Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas.

Authors:  J P Ioannidis; J Lau
Journal:  JAMA       Date:  2001 Jan 24-31       Impact factor: 56.272

4.  Statistical issues in studies of toxicity modifiers.

Authors:  Charles Scott
Journal:  Semin Radiat Oncol       Date:  2002-01       Impact factor: 5.934

5.  Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer.

Authors:  Avraham Eisbruch; Teresa Lyden; Carol R Bradford; Laura A Dawson; Marc J Haxer; Amy E Miller; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Jeffrey E Terrell; Gregory T Wolf
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-05-01       Impact factor: 7.038

6.  Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.

Authors:  S Staar; V Rudat; H Stuetzer; A Dietz; P Volling; M Schroeder; M Flentje; H E Eckel; R P Mueller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-08-01       Impact factor: 7.038

7.  A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

Authors:  K K Fu; T F Pajak; A Trotti; C U Jones; S A Spencer; T L Phillips; A S Garden; J A Ridge; J S Cooper; K K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-08-01       Impact factor: 7.038

8.  Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.

Authors:  E E Vokes; M S Kies; D J Haraf; K Stenson; M List; R Humerickhouse; M E Dolan; H Pelzer; L Sulzen; M E Witt; Y C Hsieh; B B Mittal; R R Weichselbaum
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

9.  Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.

Authors:  M S Kies; D J Haraf; F Rosen; K Stenson; M List; B Brockstein; T Chung; B B Mittal; H Pelzer; L Portugal; A Rademaker; R Weichselbaum; E E Vokes
Journal:  J Clin Oncol       Date:  2001-04-01       Impact factor: 44.544

10.  Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.

Authors:  Johannes A Langendijk; Patricia Doornaert; Irma M Verdonck-de Leeuw; Charles R Leemans; Neil K Aaronson; Ben J Slotman
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

View more
  15 in total

Review 1.  Systematic review of dose--volume correlates for structures related to late swallowing disturbances after radiotherapy for head and neck cancer.

Authors:  Fréderic Duprez; Indira Madani; Bruno De Potter; Tom Boterberg; Wilfried De Neve
Journal:  Dysphagia       Date:  2013-02-22       Impact factor: 3.438

2.  Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer.

Authors:  Ester Orlandi; Rosalba Miceli; Gabriele Infante; Aurora Mirabile; Daniela Alterio; Maria Cossu Rocca; Nerina Denaro; Riccardo Vigna-Taglianti; Annamaria Merlotti; Antonio Schindler; Nicole Pizzorni; Carlo Fallai; Lisa Licitra; Paolo Bossi
Journal:  Dysphagia       Date:  2018-06-08       Impact factor: 3.438

3.  The first real-time intrafraction target position monitoring in pancreas SBRT on an Elekta linear accelerator.

Authors:  Sankar Arumugam; Darren Pavey; Andrew Oar; Lois Holloway; Mark Sidhom; Mark Lee
Journal:  Phys Eng Sci Med       Date:  2021-05-21

Review 4.  Oropharyngeal dysphagia: manifestations and diagnosis.

Authors:  Nathalie Rommel; Shaheen Hamdy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

5.  Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates.

Authors:  Avraham Eisbruch; Hyungjin M Kim; Felix Y Feng; Teresa H Lyden; Marc J Haxer; Mary Feng; Frank P Worden; Carol R Bradford; Mark E Prince; Jeffrey S Moyer; Gregory T Wolf; Douglas B Chepeha; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-17       Impact factor: 7.038

6.  Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes.

Authors:  Klaudia U Hunter; Matthew Schipper; Felix Y Feng; Teresa Lyden; Mark Haxer; Carol-Anne Murdoch-Kinch; Benjamin Cornwall; Connie S Y Lee; Douglas B Chepeha; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-03       Impact factor: 7.038

7.  Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.

Authors:  Stuart E Samuels; Yebin Tao; Teresa Lyden; Marc Haxer; Matthew Spector; Kelly M Malloy; Mark E Prince; Carol R Bradford; Francis P Worden; Matthew Schipper; Avraham Eisbruch
Journal:  Oral Oncol       Date:  2016-01-06       Impact factor: 5.337

8.  Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors.

Authors:  Klaudia U Hunter; Oliver E Lee; Teresa H Lyden; Marc J Haxer; Felix Y Feng; Mathew Schipper; Francis Worden; Mark E Prince; Scott A McLean; Gregory T Wolf; Carol R Bradford; Douglas B Chepeha; Avraham Eisbruch
Journal:  Head Neck       Date:  2013-06-01       Impact factor: 3.147

9.  Efficacy of induction selection chemotherapy vs primary surgery for patients with advanced oral cavity carcinoma.

Authors:  Steven B Chinn; Matthew E Spector; Emily L Bellile; Laura S Rozek; Tasha Lin; Theodoros N Teknos; Mark E Prince; Carol R Bradford; Susan G Urba; Thomas E Carey; Avraham Eisbruch; Gregory T Wolf; Francis P Worden; Douglas B Chepeha
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-02       Impact factor: 6.223

10.  Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): Scale development and validation.

Authors:  Katherine A Hutcheson; Martha P Barrow; Denise A Barringer; Jodi K Knott; Heather Y Lin; Randal S Weber; Clifton D Fuller; Stephen Y Lai; Clare P Alvarez; Janhavi Raut; Cathy L Lazarus; Annette May; Joanne Patterson; Justin W G Roe; Heather M Starmer; Jan S Lewin
Journal:  Cancer       Date:  2016-08-26       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.